Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells 10,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $111.93, for a total value of $1,119,300.00. Following the sale, the chief operating officer now directly owns 207,503 shares in the company, valued at $23,225,810.79. The transaction was disclosed in a filing with the SEC, which is available at this link.

Jim Wassil also recently made the following trade(s):

• On Monday, July 1st, Jim Wassil sold 3,000 shares of Vaxcyte stock. The shares were sold at an average price of $76.34, for a total transaction of $229,020.00.

Vaxcyte Trading Up 2.7 %

PCVX opened at $112.10 on Friday. The business’s 50 day moving average is $81.08 and its 200-day moving average is $73.28. The stock has a market cap of $12.20 billion, a PE ratio of -26.19 and a beta of 0.97. Vaxcyte, Inc. has a twelve month low of $44.20 and a twelve month high of $119.27.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.12). During the same period in the prior year, the business posted ($0.70) earnings per share. As a group, analysts forecast that Vaxcyte, Inc. will post -4.33 EPS for the current year.

Institutional Investors Weigh In On Vaxcyte

Several institutional investors have recently bought and sold shares of PCVX. Darwin Global Management Ltd. lifted its position in Vaxcyte by 374.3% in the first quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock worth $187,907,000 after purchasing an additional 2,170,845 shares during the period. Vanguard Group Inc. raised its stake in shares of Vaxcyte by 15.2% in the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after buying an additional 1,284,883 shares in the last quarter. Norges Bank acquired a new stake in shares of Vaxcyte in the fourth quarter valued at $57,494,000. Capital Research Global Investors boosted its stake in Vaxcyte by 20.4% during the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after buying an additional 700,414 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in Vaxcyte by 9.9% during the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock worth $524,117,000 after acquiring an additional 692,492 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PCVX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th. Needham & Company LLC raised their target price on shares of Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a report on Tuesday. Jefferies Financial Group upped their target price on Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday. Leerink Partners raised their price target on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, BTIG Research boosted their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $131.83.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.